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Abstract 
Atherosclerosis was believed to be an inevitable consequence 
of aging. In the early eighties, oxidation of lipoproteins as a cause 
of atherosclerosis was proposed. It is now recognized that oxidized 
Low Density Lipoprotein (LDL) is not only a biomarker of 
atherosclerosis, but also a cause for it. LDL is a complex particle 
made up of cholesterol, cholesterol ester, phospholipids, 
triglycerides and one molecule of the protein Apo B. Since LDL 
and its components are susceptible to oxidation to varying extents, 
the actual species of oxidized LDL that is atherogenic in currently 
unidentified.Although oxidized LDL is detected in atherosclerotic 
plaques, the mechanism of in vivo oxidation has remained elusive. 
The only mechanism that has been deduced is from its in vitro 
oxidation., LDL undergoes distinct phase of oxidation in vitro and 
progresses through minimally modified LDL to completely 
oxidized LDL . The presence of unsaturated fatty acids in LDL 
make them more susceptibility to oxidation. With the surprising 
discovery of fatty streaks in the arteries of even new born babies, it 
is evident that everyone is born with a possibility of developing 
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atherosclerosis. Whether the atherosclerosis regresses or 
progresses depends on the life style. 
 
Key Words: Atherosclerosis, LDL, Oxidized LDL.   
  Atherosclerosis is a word derived from the Greek languages; ‘arteria’ 
meaning gruel and ‘sclerosis’ meaning hardening. Atherosclerosis or hardening of 
gruel like substance in the arteries results in reducing the diameter of the arteries, 
and was believed to be an inevitable consequence of aging. In 1815, Hodgson 
published a monograph when he claimed that inflammation was the underlying 
cause of atherosclerosis (Hodgson 1815). In 1858, Virchow reported the presence 
of inflammatory cells in the atherosclerotic lesion and proposed that local injury 
to intima was the initiating stimulus for atherosclerosis (Meng 2005). However, 
the inflammation hypothesis was ignored for over a century in favor of the 
cholesterol theory which was put forth much later (Ravnskov 2002). 
Several studies including Framingham study have shown that elevated 
serum cholesterol in an independent risk factor for heart diseases (Expert panel  
2001, Heart Protection Study Collaborative Group 2002). However, for a given 
individual measurement of serum total cholesterol was useless in predicting the 
risk of heart diseases. Several studies showed that cholesterol did not correlate 




The discovery of lipoproteins in the blood carrying cholesterol and lipids 
gave a new lease to the cholesterol theory of heart diseases. High levels of low 
density lipoprotein (LDL) correlated with risk of cardiovascular diseases (CVD) 
better than high total cholesterol (Tomkins and Owens 2012). Hence LDL became 
the target of therapy for prevention of heart diseases (Steinberg et al. 1989). 
However, more than half of patients who had cardiac events were those whose 
LDL was in the optimal range.  
In the early eighties the theory of oxidation as a cause of atherosclerosis 
was proposed (Parthasarathy 2010). According to this theory, LDL can undergo 
oxidation resulting in Oxidized LDL which is no longer recognized by the LDL-
receptor, but is recognized by the scavenger receptor of macrophages 
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(Steinbrecher et al. 1984) .It is now increasingly clear that oxidized LDL is not 
only a biomarker for atherosclerosis but also a cause for it. The ability of oxidized 
LDL to generate plaques has been investigated for over three decades. When LDL 
is oxidized in the intima, monocytes from the blood migrate to the intimal space 
to repair or remove the oxidized LDL. Repair mechanism involves monocyte/ 
macrophage accumulation in an effort to clear cholesterol from the plaque. The 
macrophage does not have an LDL receptor and can only take up modified LDL. 
Modifications include oxidation, and glycation which can occur in the sub 
endothelial space. Once the macrophage takes up the LDL and becomes a foam 
cell it should be hypothetically be able to remove cholesterol to the reticulo-
endothelial system for clearance but in the atherosclerotic process the macrophage 
gets trapped in the intima and is unable to escape due to the increase in size. 
When the LDL cannot be repaired it is removed by phagocytosis (Picard et al. 
1992). These monocytes are unable to limit the level of oxidized LDL they 
engulph which results in an overload of lipids. The cells appear as “foam”filled 
and hence are called as foam cells. Foam cells are biologically active and signal 
the endothelium to recruit more monocytes. The smooth muscle cells also are 
recruited. Thus the process results in pushing up of the endothelial cell layer 
resulting in narrowing of arteries (Miller et al. 2003, Miller et al. 2005). Since 
LDL-oxidation can result in the initiation of this process, elevated LDL had a 
higher risk of elevated oxidized LDL. It is apparent that the LDL particle depends 
for its atherogenicity to a large extent on its ability to be modified. The 
modification that has drawn a lot of attention is oxidation. Essentially the release 
of free radicals is enhanced from conditions such as hyperglycaemia, ischaemia, 
and infection. The free radicals would be available to oxidise the LDL particle 
(Steinberg and Witztum, 2010). The major sites of oxidation on the LDL particle 
include Apo B and the polyunsaturated fatty acids but cholesterol and 
phospholipids can also be oxidised. There is one apo B molecule per particle and 
hence Apo B is considered a strong risk marker for atherosclerosis. The amount of 
oxidised phospholipid on LDL apo B100 appears to be a good marker of 
atherosclerotic progression (Ahmadi et al 2010). 
The formation of atherosclerotic plaque requires that the LDL be attached 
to the endothelial surface. Once the LDL particle has been attached to the 
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endothelial surface further changes must occur before the cholesterol-rich particle 
becomes part of the atherosclerotic plaque. LDL aggregation seems very 
important in this process. The mechanism whereby LDL particles fuse and 
coalesce into lipid droplets and thereby increase LDL in the artery wall is 
complex (Oorni et al 2000). Jayaraman et al., (2011) demonstrated that free fatty 
acids enhance LDL coalescence into lipid droplets. They suggest that lipid droplet 
formation contributes to the pro-atherogenic effects of FFA on LDL. Most of the 
lipids found in atherosclerotic plaques are present in lipid droplets and LDL 
derived small lipid droplets are prominent in atherosclerotic lesions (Asplund et al 
2011). Modifications such as oxidation, lipolysis and proteolysis are prerequisites 
for droplet fusion. Enzymes from the Phospolipase A2 (PLA2) family hydrolyse 
phosphatidyl choline. Lipoprotein associated PLA2 preferentially hydrolyses 
oxidised phosphotidyl cholines in LDL and may promote fusion of LDL particles 
and thus contribute to its enhanced atherogenicity (Guyton and Klemp 1994). 
Thus lipoprotein associated Phospholipase A2 has emerged as a causative agent of 
atherosclerosis and as a new therapeutic target. 
LDL-subtypes and LDL-oxidation:  
Based on its density LDL has been sub classified into at least three classes. 
The large LDL, medium LDL and small dense LDL have been separated and 
classified (Austin and Krause 1995, Kraus and Burke 1982) .The size of the LDL 
particle is about the same as the space between two adjacent endothelial cells, 
which is about 26nm.Particles of diameter less than 20.5nm are called as small 
dense LDL(Koba et al. 2008).These particles can easily pass through the gaps 
between endothelial cells and enter the intimal space where they can get 
oxidized.(Phillips et al. 2005) Although there is no clinically relevant  method to 
measure the amount of small dense LDL,it has been shown that individuals with 
high density lipoprotein (HDL-C) less than 35mg/dl and Triglycerides more than 
250mg/dl have small dense LDL. LDL particle when it has moved out of the 
blood into the intima, it is out of reach of antioxidants present in the blood. Hence 
it is susceptible to oxidative modification.An atherosclerotic plaque is an ideal 
location for the oxidation of LDL.  
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The LDL particle contains about 1600 molecules of cholesterol ester and 
about 170 molecules of triglycerides, which form a hydrophobic core of the 
particle. This is surrounded by about 700 molecules of phospholipids consisting 
mainly of Phosphatidylcholine(PC) and a small amount of sphingomyelin and 
lyso PC, and about 600 molecules of free cholesterol.This particle contains one 
molecule of the protein Apo B with 4536namino acid residues. The LDL particle 
has about 2700 fatty acid molecules esterified with various molecules of the 
particle (Jialal and Devaraj 1996) .About half of these fatty acids are 
polyunsaturated. Since the composition of the poly unsaturated fatty acid(PUFA) 
in the LDL particle is variable and since the particle contains varying amounts of 
anti oxidants like α-Tocopherol, LDL oxidation proceeds by multiple 
mechanisms, particularly when the oxidation is induced by different 
oxidants(Steinberg and Witztum 2010). Thus it is difficult to define what is 
actually oxidized LDL since there can be a variety of lipid and protein oxidation 
products as well as changes in the physical structure and properties (chehin 2001). 
Which of these is actually atherogenic is impossible to identify currently.  
Mechanism of in vitro oxidation:  
In vitro oxidation of LDL has been a convenient model to understand the 




 to initiate LDL oxidation 
in vitro (Quehenberger 1988) .The oxidation of LDL has been shown to proceed 
through well defined phases. Once the oxidation has been initiated the lipids of 
the LDL particle undergo oxidation by free radical catalyzed mechanism (Young 
and McEneny 2001).The conjugated double bond of polyunsaturated fatty acids of 
the lipid molecules in the primary target of the oxidant. The reactive methylene 
group between the two double bonds loses a proton. This is the key step in the 
initiation of lipid oxidation. The unstable radical then rearranges the double bond 
to give a conjugated diene. This conjugated dienes absorbs UV light maximally at 
234nm and provides a convenient method for monitoring the progression of 
oxidation ( Lynch and Frei 1993). 
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In the presence of antioxidants, the oxidative effect of pro oxidants can be 
minimized or abolished. Thus the antioxidant present on LDL particle can prevent 
the lipid oxidation and there will be no 234nm absorbing conjugated dienes 
formed. This phase is called as the lag phase. The length of this phase is decided 
by the amount of antioxidant present on the LDL particle and the nature of the 
oxidant (Aviram and Fuhrman 1998). 
  Once the antioxidants are consumed, the lipids of LDL get rapidly oxidized with 
a large increase in the absorbance at 234nm.This is called as propagation phase. 
The propagation phase reaches a plateau where no more 234nm absorbing 
substances are formed. 
If the oxidation is continued further, more and more oxidation products of 
lipids will be formed by cleaving the conjugated dienes. Thus if oxidation is 
monitored further, there will be a decline in the conjugated dienes and this phase 
is called the decline phase. In this phase, the lipid degradation products would 
react with the protein part of the LDL particle. The amino groups of proteins are 
highly susceptible to reaction with lipid oxidation products like aldehydes and 
ketones. At this stage the LDL particle is no larger recognized by the LDL-
receptor and hence it has to be cleared by the scavenger cells through binding the 
scavenger receptor. 
Oxidation of LDL in vivo:  
There is adequate evidence to suggest that the process of LDL oxidation 
seen in vitro studies is also taking place in vivo. Several cell types produce 
powerful oxidants as anti microbial defense. Mitochondrial oxidation can also 
produce oxygen free radicals. When pro oxidants are more than the anti oxidants, 
they can cause LDL oxidation. Thus pro inflammatory stimuli can initiate 
oxidative steps resulting in LDL oxidation.  
Conclusion:  
Whatever the cause of initiation of LDL-oxidation, it can be a powerful 
initiating factor for atherosclerosis. Once initiated the atherosclerosis progresses 
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until the end point is reached namely the death of the individual. Surprisingly, 
even new born babies were found to have the fatty streaks in their arteries (Napoli 
et al 1997). This implies that everyone is born with a possibility of developing 
atherosclerosis. The life style one chooses decides whether this regresses or 
progress of full blown atherosclerosis.   
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